CAS 441045-17-6

Eribulin mesylate

Description:

Eribulin mesylate is a synthetic analog of halichondrin B, a natural product derived from marine sponges, and is classified as a microtubule dynamics inhibitor. It is primarily used in the treatment of metastatic breast cancer and liposarcoma. The compound works by disrupting the normal function of microtubules, thereby inhibiting cell division and promoting apoptosis in cancer cells. Eribulin is characterized by its unique structure, which includes a complex polyether backbone and a mesylate salt form that enhances its solubility and stability. It is administered intravenously and has a specific pharmacokinetic profile, with a half-life that allows for effective dosing schedules. Common side effects include fatigue, neutropenia, and peripheral neuropathy. Eribulin's mechanism of action and its ability to overcome resistance to other chemotherapeutic agents make it a valuable option in oncology. Its development underscores the importance of natural products in drug discovery and the potential for marine-derived compounds in cancer therapy.

Formula: C₄₀H₅₉NO₁₁·CH₄O₃S

InChI: InChI=1S/C40H59NO11.CH4O3S/c1-19-11-24-5-7-28-20(2)12-26(45-28)9-10-40-17-33-36(51-40)37-38(50-33)39(52-40)35-29(49-37)8-6-25(47-35)13-22(42)14-27-31(16-30(46-24)21(19)3)48-32(34(27)44-4)15-23(43)18-41;1-5(2,3)4/h19,23-39,43H,2-3,5-18,41H2,1,4H3;1H3,(H,2,3,4)/t19-,23+,24+,25-,26+,27+,28+,29+,30-,31+,32-,33-,34-,35+,36+,37+,38-,39+,40+;/m1./s1

InChI key: InChIKey=QAMYWGZHLCQOOJ-WRNBYXCMSA-N

SMILES: C=C1C[C@@]2(CC[C@@]34O[C@@]5([C@]6([C@]([C@@](O3)([C@@](C4)(O6)[H])[H])(O[C@@]7([C@@]5(O[C@](CC7)(CC(=O)C[C@]8([C@@](O[C@H](C[C@@H](CN)O)[C@@H]8OC)(C[C@]9(O[C@@](CC[C@@]1(O2)[H])(C[C@@H](C)C9=C)[H])[H])[H])[H])[H])[H])[H])[H])[H])[H])[H].S(C)(=O)(=O)O

Synonyms:

• 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-I]furo[2',3':5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-,2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-,methanesulfonate (salt)
• 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2′,3′:5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (1:1)
• 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano-9H,15H-furo[3,2-i]furo[2′,3′:5,6]pyrano[4,3-b][1,4]dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2-hydroxypropyl]hexacosahydro-3-methoxy-26-methyl-20,27-bis(methylene)-, (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS)-, methanesulfonate (salt)
• E 7389 methanesulfonate
• E7389
• Eribulin Mesylate
• Halaven

Eribulin mesylate

CAS: 441045-17-6

Formula: C₄₁H₆₃NO₁₄S

Purity: 98%

Color and Shape: Solid

Molecular weight: 826.0022

Ref: IN-DA00DB5V

Eribulin mesylate

CAS: 441045-17-6

Eribulin mesylate

Purity: ≥95%

Molecular weight: 826g/mol

Ref: 54-BUP06799

Eribulin Mesylate

CAS: 441045-17-6

Formula: C₄₀H₅₉NO₁₁·CH₄O₃S

Color and Shape: Pale Yellow Solid

Molecular weight: 729.91 96.10

Ref: 4Z-E-110001

Eribulin mesylate

CAS: 441045-17-6

Eribulin mesylate (E7389), a microtubule inhibitor, treats metastatic breast cancer by halting cell division.

Formula: C₄₁H₆₃NO₁₄S

Purity: 97.02% - >99.99%

Color and Shape: Solid

Molecular weight: 826

Ref: TM-T13687

Eribulin Mesilate RS

CAS: 441045-17-6

Color and Shape: White Solid Powder

Ref: 2K-1028700021

Eribulin mesylate

CAS: 441045-17-6

Purity: 98%

Molecular weight: 826.01

Ref: 10-F979042

Eribulin mesylate

CAS: 441045-17-6

Eribulin mesylate is a drug that inhibits the growth of cancer cells. It is a synthetic taxane that binds to and prevents the function of topoisomerase I, which is essential for DNA replication, transcription, and cell division. Eribulin mesylate has been shown to be effective in treating breast cancer and platinum-resistant ovarian cancer. The side-effect profiles of this drug are low when compared with other chemotherapeutic agents because it does not have a significant effect on the central nervous system or bone marrow. Eribulin mesylate also has potential as a biomarker for assessing treatment efficacy and resistance to chemotherapy in solid tumours.

Formula: C₄₀H₅₉NO₁₁•CH₄O₃S

Purity: Min. 95%

Color and Shape: White Powder

Molecular weight: 826 g/mol

Ref: 3D-FE30646